We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

93 hedge funds and large institutions have $69.1M invested in Cartesian Therapeutics in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 25 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

988% more call options, than puts

Call options by funds: $87K | Put options by funds: $8K

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

11% more funds holding

Funds holding: 84 → 93 (+9)

9% more capital invested

Capital invested by funds: $63.3M → $69.1M (+$5.8M)

0.19% less ownership

Funds ownership: 1.21% → 1.02% (-0.19%)

20% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 25

Holders
93
Holders Change
+9
Holders Change %
+10.71%
% of All Funds
1.48%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
20
Reduced
25
Closed
15
Calls
$87K
Puts
$8K
Net Calls
+$79K
Net Calls Change
+$109K

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$3.64M
2
NCM
Nantahala Capital Management
Connecticut
+$1.57M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.29M
4
HSBC Holdings
HSBC Holdings
United Kingdom
+$940K
5
BCM
Bridgeway Capital Management
Texas
+$682K

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$5.94M
2
EC
EcoR1 Capital
California
-$5.17M
3
ABG
Ally Bridge Group
New York
-$2.89M
4
ECM
Endurant Capital Management
California
-$2.52M
5
BI
BVF Inc
California
-$1.57M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$612K -$254K -5,406 -27%
BCM
27
Bridgeway Capital Management
Texas
$605K +$682K +14,500 New
State Street
28
State Street
Massachusetts
$586K – – –
Ameriprise
29
Ameriprise
Minnesota
$540K +$173K +3,673 +40%
Goldman Sachs
30
Goldman Sachs
New York
$536K +$482K +10,252 +394%
HF
31
HRT Financial
New York
$532K +$600K +12,766 New
GCP
32
GSA Capital Partners
United Kingdom
$462K -$61.7K -1,312 -11%
BCM
33
BlueCrest Capital Management
Jersey
$459K +$518K +11,010 New
First Trust Advisors
34
First Trust Advisors
Illinois
$425K +$36.5K +777 +8%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$405K -$109K -2,316 -19%
Morgan Stanley
36
Morgan Stanley
New York
$373K +$196K +4,166 +87%
Northern Trust
37
Northern Trust
Illinois
$290K -$7.94K -169 -2%
Two Sigma Investments
38
Two Sigma Investments
New York
$280K -$182K -3,873 -37%
EC
39
EcoR1 Capital
California
$278K -$5.17M -110,000 -94%
Man Group
40
Man Group
United Kingdom
$270K -$245K -5,206 Closed
Citigroup
41
Citigroup
New York
$265K -$177K -3,760 -37%
IIM
42
Ironwood Investment Management
Massachusetts
$263K +$18.3K +389 +7%
Jane Street
43
Jane Street
New York
$250K +$282K +6,001 New
Squarepoint
44
Squarepoint
New York
$154K +$174K +3,698 New
CIC
45
Cornercap Investment Counsel
Georgia
$140K – – –
Bank of America
46
Bank of America
North Carolina
$136K +$76.2K +1,620 +99%
JF
47
Jump Financial
Illinois
$127K +$144K +3,053 New
PCS
48
Personal CFO Solutions
New Jersey
$118K – – –
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$105K +$611 +13 +0.5%
LP
50
LMR Partners
United Kingdom
$93.3K +$105K +2,236 New
1
2
3 4 5

RNAC Hedge Fund Activity: Q1 2023 in Review

93 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2023, worth a combined $69.1M — up 9.2% from $63.3M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new RNAC positions and 15 closed out — a net gain of 9 holders — while 20 added to existing stakes and 25 trimmed.

The largest buyer was Sphera Funds Management, opening a new position worth an estimated $3.64M. The largest seller was Mangrove Partners, exiting entirely with an estimated $5.94M sold.

  • 93 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2023, up from 84 in Q4 2022.
  • Funds reported $69.1M of Cartesian Therapeutics stock for Q1 2023, up 9.2% quarter-over-quarter.
  • 24 funds opened new Cartesian Therapeutics positions in Q1 2023 and 15 closed out, a net change of +9 holders.
  • The largest Cartesian Therapeutics buyer in Q1 2023 was Sphera Funds Management, an estimated $3.64M added.
  • The largest Cartesian Therapeutics seller in Q1 2023 was Mangrove Partners, an estimated $5.94M sold.

Based on aggregated 13F filings for Q1 2023.